首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDGFD |
| Uniprot No | Q9GZP0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 250-370aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMSYHDR KSKVDLDRLN DDAKRYSCTP RNYSVNIREE LKLANVVFFP RCLLVQRCGG NCGCGTVNWR SCTCNSGKTV KKYHEVLQFE PGHIKRRGRA KTMALVDIQL DHHERCDCIC SSRPPR |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDGFD重组蛋白的3篇代表性文献概览(注：文献信息为模拟示例，实际引用请核实原文)：
---
1. **文献名称**：*"Recombinant PDGF-D induces fibroblast proliferation and extracellular matrix synthesis in vitro"*
**作者**：Reigstad, S.M., et al.
**摘要**：该研究首次报道了PDGFD重组蛋白的制备及其功能。通过哺乳动物细胞表达系统纯化获得活性PDGFD蛋白，发现其能显著促进成纤维细胞增殖和胶原蛋白分泌，提示其在组织修复和纤维化疾病中的潜在作用。
---
2. **文献名称**：*"PDGF-D promotes tumor growth and metastasis in a xenograft model of breast cancer"*
**作者**：Cao, Y., et al.
**摘要**：研究利用重组PDGFD蛋白处理乳腺癌细胞，发现其通过激活PDGFR-β信号通路增强肿瘤血管生成和侵袭能力。动物实验显示PDGFD过表达显著加速肿瘤转移，表明其作为癌症治疗靶点的可能性。
---
3. **文献名称**：*"Structural characterization of recombinant human PDGF-D and its receptor binding specificity"*
**作者**：Li, X., et al.
**摘要**：通过X射线晶体学解析了重组人PDGFD的三维结构，揭示其独特的二硫键构象。研究证实PDGFD特异性结合PDGFR-β而非PDGFR-α，为设计靶向抑制剂提供了结构基础。
---
如需具体文献，建议通过PubMed或Web of Science以“PDGFD recombinant protein”“PDGF-D signaling”为关键词检索近年研究。
Platelet-derived growth factor D (PDGFD) is a secreted glycoprotein belonging to the PDGF family, which plays critical roles in cellular proliferation, migration, and tissue remodeling. Discovered in the early 2000s, PDGFD shares structural homology with other PDGF ligands (PDGF-A, -B, -C), featuring a conserved growth factor domain and a unique C-terminal CUB domain. Unlike PDGF-A and -B, PDGFD is synthesized as an inactive precursor requiring proteolytic cleavage (e.g., by furin-like proteases) to release the bioactive dimer. It primarily signals through PDGF receptor-β (PDGFR-β), inducing receptor dimerization and activating downstream pathways like PI3K/Akt and MAPK, which regulate angiogenesis, fibroblast activation, and extracellular matrix deposition.
Recombinant PDGFD is engineered using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. Purification typically involves affinity chromatography, yielding high-purity proteins validated via SDS-PAGE and functional assays. Its applications span basic research—studying mechanisms in development, wound healing, and vascular biology—and drug discovery, particularly in pathologies like cancer, fibrosis, and cardiovascular diseases. PDGFD overexpression is linked to tumor progression via stromal interactions and angiogenesis, making it a potential therapeutic target. However, its dual role in tissue repair and disease pathogenesis necessitates careful evaluation in therapeutic contexts. Recombinant PDGFD thus serves as a vital tool for dissecting PDGF signaling and developing targeted interventions.
×
